We have focused here on how versican may contribute to immune-excluded tumours that have poor response to therapy and tumour-supporting innate and adaptive immune cell phenotypes, and identified two mechanisms though which this occurs, by biochemical and biophysical cues. This evidence concerns the gene VCAN and neoplasm.